Vericel Corp (NASDAQ: VCEL) has a higher price-to-earnings ratio of 223.35x compared to its average ratio. VCEL has 36-month beta value of 1.30. Analysts have mixed views on the stock, with 7 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VCEL is 49.61M, and currently, short sellers hold a 8.01% ratio of that float. The average trading volume of VCEL on April 18, 2025 was 445.13K shares.
VCEL) stock’s latest price update
Vericel Corp (NASDAQ: VCEL)’s stock price has soared by 1.00 in relation to previous closing price of 40.82. Nevertheless, the company has seen a loss of -1.60% in its stock price over the last five trading days. seekingalpha.com reported 2025-03-05 that Vericel’s niche in regenerative medicine is undervalued, with FDA-approved products like MACI, Epicel, and NexoBrid driving steady revenue growth and profitability. The company’s strong financials include $167 million in cash, zero debt, and a 16% year-over-year revenue increase, highlighting operational efficiency. MACI’s expansion into ankle cartilage repair and a robust pipeline suggest significant future earnings potential, despite current market hesitations.
VCEL’s Market Performance
VCEL’s stock has fallen by -1.60% in the past week, with a monthly drop of -13.07% and a quarterly drop of -26.83%. The volatility ratio for the week is 4.89% while the volatility levels for the last 30 days are 5.70% for Vericel Corp The simple moving average for the past 20 days is -4.97% for VCEL’s stock, with a -17.64% simple moving average for the past 200 days.
Analysts’ Opinion of VCEL
Many brokerage firms have already submitted their reports for VCEL stocks, with Canaccord Genuity repeating the rating for VCEL by listing it as a “Buy.” The predicted price for VCEL in the upcoming period, according to Canaccord Genuity is $57 based on the research report published on August 09, 2024 of the previous year 2024.
TD Cowen, on the other hand, stated in their research note that they expect to see VCEL reach a price target of $55. The rating they have provided for VCEL stocks is “Buy” according to the report published on June 20th, 2024.
Truist gave a rating of “Buy” to VCEL, setting the target price at $51 in the report published on January 25th of the previous year.
VCEL Trading at -14.96% from the 50-Day Moving Average
After a stumble in the market that brought VCEL to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.56% of loss for the given period.
Volatility was left at 5.70%, however, over the last 30 days, the volatility rate increased by 4.89%, as shares sank -12.61% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.28% lower at present.
During the last 5 trading sessions, VCEL fell by -1.60%, which changed the moving average for the period of 200-days by -8.44% in comparison to the 20-day moving average, which settled at $43.39. In addition, Vericel Corp saw -24.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VCEL starting from Colangelo Dominick, who sale 24,850 shares at the price of $41.89 back on Apr 10 ’25. After this action, Colangelo Dominick now owns 260,354 shares of Vericel Corp, valued at $1,040,966 using the latest closing price.
Colangelo Dominick, the President and CEO of Vericel Corp, sale 24,850 shares at $41.11 during a trade that took place back on Apr 09 ’25, which means that Colangelo Dominick is holding 260,354 shares at $1,021,584 based on the most recent closing price.
Stock Fundamentals for VCEL
Current profitability levels for the company are sitting at:
- 0.02 for the present operating margin
- 0.73 for the gross margin
The net margin for Vericel Corp stands at 0.04. The total capital return value is set at 0.01. Equity return is now at value 4.00, with 2.64 for asset returns.
Based on Vericel Corp (VCEL), the company’s capital structure generated 0.25 points at debt to capital in total, while cash flow to debt ratio is standing at 0.59. The debt to equity ratio resting at 0.34. The interest coverage ratio of the stock is 7.36.
Currently, EBITDA for the company is 16.63 million with net debt to EBITDA at 1.46. When we switch over and look at the enterprise to sales, we see a ratio of 8.82. The receivables turnover for the company is 3.87for trailing twelve months and the total asset turnover is 0.55. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.23.
Conclusion
To put it simply, Vericel Corp (VCEL) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
